Health

Add as a preferred source on Google

Amplia Therapeutics Wins Ethics Approval for Australian Cancer Trial

The ACCENT-Mini study will test daily narmafotinib with chemotherapy in metastatic pancreatic cancer. Amplia expects initial safety and drug behavior data in late Q1 or early Q2 2027.

Updated 1 min read
A chemotherapy infusion is prepared in an oncology unit in Australia. (AI-generated image / EconoTimes)
A chemotherapy infusion is prepared in an oncology unit in Australia. (AI-generated image / EconoTimes)

Amplia Therapeutics Limited has received ethics approval for an Australian trial testing daily narmafotinib with chemotherapy in metastatic pancreatic cancer, moving the study closer to recruiting patients after site approvals are complete.

The ACCENT-Mini trial will combine narmafotinib with gemcitabine and Abraxane. Amplia said three clinical trial sites in Australia have been selected and start-up work is well advanced.

The study follows Amplia’s ACCENT trial, which tested narmafotinib given intermittently alongside chemotherapy. The company reported a 7.8% complete response rate and median overall survival of 11.1 months in ACCENT. ACCENT-Mini will evaluate a daily dosing schedule.

Amplia expects initial safety results and information on how the drug behaves in the body by late Q1 or early Q2 2027. The company plans to include those data in a protocol submission to the U.S. Food and Drug Administration for a registrational study of narmafotinib in pancreatic cancer.

Narmafotinib is Amplia’s candidate drug targeting focal adhesion kinase, or FAK. The company says tumors can become resistant to existing treatments and newer targeted medicines, including KRAS inhibitors, limiting their effectiveness.

Dr. Chris Burns, Amplia’s CEO and managing director, said patients with metastatic pancreatic cancer have limited treatment options. Burns said Amplia looked forward to exploring whether daily narmafotinib with chemotherapy could improve outcomes.

Related articles

View all